Vildegliptin superior to glimepiride when added to metformin
As reported in Metabolism, addition of vildegliptin (50 mg bid) to metformin in T2DM patients inadequately controlled on metformin alone was superior to the addition of glimepiride (2 mg tid) to metformin. Patients on the vildegliptin + metformin regimen lost more weight, had an improved lipid profile, had increased insulin sensitivity, and decreased post-prandial lipemia and insulinemia compared to patients on the glimepiride + metformin regimen.
TNFR1 predicts all-cause mortality in diabetic kidney disease
As reported in Diabetes Care, type 2 diabetics (n=522) with diabetic kidney disease (eGFR< 60 or urinary albumin-to-creatinine ratio > 30 mg/mmol) with TNFR1 levels in the highest quartile were at increased risk of all-cause mortality compared to diabetics with TNFR1 levels in the lowest quartile (aHR = 2.98). One hundred ninety-six deaths occurred in 48 months of follow-up.
Decreased survival in diabetic patients with pancreatic cancer
As reported in the British Journal of Cancer, patients with diabetes (n=62) are at increased risk of death from pancreatic cancer overall (HR=1.52) and within 3 years of diagnosis (HR=1.45).